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ABSTRACT
Myeloid elf-1-like factor (MEF) or Elf4 is an
E-twenty-six (ETS)-related transcription factor with
strong transcriptional activity that influences
cellular senescence by affecting tumor suppressor
p53. MEF downregulates p53 expression and
inhibits p53-mediated cellular senescence by tran-
scriptionally activating MDM2. However, whether
p53 reciprocally opposes MEF remains unex-
plored. Here, we show that MEF is modulated by
p53 in human cells and mice tissues. MEF expres-
sion and promoter activity were suppressed by p53.
While we found that MEF promoter does not contain
p53 response elements, intriguingly, it contains E2F
consensus sites. Subsequently, we determined that
E2F1 specifically binds to MEF promoter and
transactivates MEF. Nevertheless, E2F1 DNA
binding and transactivation of MEF promoter was
inhibited by p53 through the association between
p53 and E2F1. Furthermore, we showed that activa-
tion of p53 in doxorubicin-induced senescent cells
increased E2F1 and p53 interaction, diminished
E2F1 recruitment to MEF promoter and reduced
MEF expression. These observations suggest that
p53 down-regulates MEF by associating with and
inhibiting the binding activity of E2F1, a novel
transcriptional activator of MEF. Together with
previous findings, our present results indicate that
a negative regulatory mechanism exists between
p53 and MEF.
INTRODUCTION
MEF/ELF4 is a member of the E-twenty -six (ETS) family
of transcription factors, which function as transcriptional
activators or repressors and regulate critical aspects of
cellular differentiation, proliferation and transform-
ation (1). MEF was originally isolated from human
megakaryocytic leukemia cell line, and is known to
activate the expression of a variety of cytokine genes,
such as interleukin (IL)-3 and IL-8 (2,3) and antibacterial
peptides, such as lysozyme and human b-defensin and the
cytolytic molecule perforin (4–6). MEF expression and
activity are regulated by its post-translational modiﬁca-
tion, protein–protein interaction and by transcription.
MEF expression is highest at G1 phase; and at G1 to
S-phase transition, MEF is phosphorylated by cyclinA–
cdk2 complex, ubiquitinated by SCF
skp2 and degraded
by proteasome (7,8). SUMOylation of MEF inhibits its
transcriptional activity (9), whereas translocation of
MEF into promyelocytic leukemia (PML) nuclear bodies
induces interaction with PML and increases MEF tran-
scriptional activator function (10,11). Sp1 was previously
determined to positively inﬂuence the transcription of
MEF (12). Epigenetic regulation, promoter methylation
and histone deacetylation mediate MEF gene silencing
(our unpublished data) (13).
Besides its function as an activator of cytokines and
innate immune molecules, MEF also impacts on cell-cycle
progression by promoting the transition of cells from G1
to S phase (7). The loss of MEF was shown to increase
tumor suppressor p53 protein and enhance hematopoietic
stem cell (HSC) quiescence in murine embryonic ﬁbro-
blasts, implicating MEF in driving HSC from quiescence
to G1 phase by opposing p53 function (14,15). A study
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scription of MDM2, the E3 ubiquitin ligase of p53,
thereby suppressing p53 protein stability that led to the
inhibition of p53-dependent oncogene-induced cellular
senescence (16). Considering that MEF contributes to
driving cell-cycle progression and that MEF suppresses
p53, which is known for promoting cell-cycle arrest and
senescence, we hypothesized that p53, in turn, affects
MEF expression. Here, we present evidence that p53
downregulates MEF expression. p53 overexpression or ac-
tivation of endogenous p53 repressed MEF levels, whereas
in the absence of p53 in human epithelial cells and mice
tissues, higher MEF expression level was observed. By
investigating the mechanism of this downregulation, we
found that p53 inhibits the promoter-binding activity of
E2F1, which we also show here as a novel transcriptional
activator of MEF. Exogenous addition of E2F1
upregulated MEF expression and promoter activity; con-
versely, E2F1 knockdown reduced MEF transcription.
Furthermore, p53 inhibited the DNA binding of E2F1
to MEF promoter by associating with E2F1, which led
to the suppression of MEF levels. These ﬁndings
describe the direct positive regulation of MEF by E2F1
and the suppression of MEF by p53.
MATERIALS AND METHODS
Reagents and antibodies
Nutlin-3 was from Alexis Biochemicals (San Diego, CA,
USA). Doxorubicin was from Sigma-Aldrich Co.
(St Louis, MO, USA). Antibody for MEF was obtained
from Transgenic Inc. (Kumamoto, Japan). Mouse
anti-p53 (DO-1), rabbit anti-E2F1 (C-20), mouse IgG
(sc-2025), rabbit IgG (sc-2027) and g-tubulin (sc-7396)
antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). The horseradish
peroxidase (HRP)-conjugated secondary antibodies used
in this study were from Jackson ImmunoResearch
Laboratories, Inc. (West Grove, PA, USA).
Cell culture, treatment and transfection
Human colorectal cancer cell line, HCT116 p53
+/+ and
HCT116 p53
 /  cells were kindly provided by Dr. B.
Vogelstein from Johns Hopkins University. These cells
were maintained in Dulbecco’s modiﬁed Eagle’s
medium/Ham’s F-12 (DMEM/F12) medium supple-
mented with 10% (v/v) fetal bovine serum (FBS),
100IU/ml penicillin and 100mg/ml streptomycin. Human
bronchial epithelial cells, 16HBE14o-, were donated by
Dr. D. Gruenert from the California Paciﬁc Medical
Center (San Francisco, CA, USA). 16HBE14o- cells
were cultured in Minimum Essential medium (MEM) sup-
plemented with 10% FBS and antibiotics, and grown in
ﬁbronectin-coated dishes. Lung adenocarcinoma, A549,
and human embryonic kidney, HEK293, were maintained
in DMEM containing 10% FBS and antibiotics. Human
hepatoma cells, HepG2, were maintained in MEM supple-
mented with 10% FBS and antibiotics. A549, HEK293
and HepG2 cell lines were obtained from American
Type Culture Collection. All cell lines were cultured at
37 C in a humidiﬁed atmosphere of 5% CO2. Treatment
of cells with nutlin-3 or DMSO (control) was carried out
for 24h (HCT116 cells) or 48h (HepG2 cells). Transient
transfections of plasmids were performed using Hilymax
(Dojindo Laboratories, Kumamoto, Japan) following the
manufacturer’s recommendation. Speciﬁcally, Hilymax
diluted in Opti-MEM (Gibco) was mixed with total
DNA in a ratio of 1:4 (DNA/Hilymax) and applied to
subconﬂuent cells. Small-interfering RNA (siRNA) for
p53 or E2F1 was transfected into cells using Trans-IT
TKO (Mirus, Madison, WI, USA) according to the manu-
facturer’s instruction. p53 or E2F1 siRNA duplex (50nM)
complexed with Trans-IT TKO (1:4; siRNA/TKO ratio)
was transfected into 70% conﬂuent cells. GL2-luc siRNA
duplex was used as control. The cells were harvested 48h
after transfection. The siRNA oligonucleotide sequences
are listed in Table 1.
Real-time quantitative reverse transcriptase polymerase
chain reaction analysis
Total RNA was isolated from cells and mice tissues using
TRIzol (Invitrogen, Carlsbard, CA, USA) according to the
manufacturer’s instruction. Real-time quantitative reverse
transcriptase polymerase chain reaction (RT–PCR)
analyses for human or mouse MEF and internal controls
GAPDH or 18S ribosomal RNA (18S rRNA) were carried
out with SYBR Green Master Mix (Applied Biosystems,
Carlsbard, CA, USA) following the manufacturer’s in-
structions. PCR ampliﬁcations were performed as
describedpreviously(17).The Ctvaluesforeachgeneamp-
liﬁcation were normalized by subtracting the Ct value
calculated for GAPDH or 18S rRNA. The normalized
gene expression values were expressed as the relative
quantity of MEF gene-speciﬁc messenger RNA (mRNA).
The oligonucleotide primers used in the real-time quantita-
tive PCR ampliﬁcations are shown in Table 2.
Plasmids and luciferase assay
The cloning of MEF promoter constructs (–849/+181;
 384/+181;  204/+181bp) in luciferase reporter vector,
pGL3 basic vector, (pGL3b; Promega Corp. Madison,
WI, USA) was described previously (12). MEF promoter
constructs containing mutation/s in E2F binding sites
(MT1, MT2 and MT1&2) were prepared using
QuikChange II XL site-directed mutagenesis kit
(Stratagene. La Jolla, CA, USA) following the recom-
mended protocol. The primers used for generating MEF
mutant promoters are listed in Table 3. The p53 expres-
sion plasmid was cloned in pCDM8 expression vector as
described in (18). The E2F1 expression plasmid (Addgene
plasmid 10736) was purchased from Addgene.
For luciferase assays, HCT116 and HEK293 cells
seeded onto 12-well plates were transfected with 0.2mg
of MEF-luc promoter construct, together with 20ng of
Renilla luciferase plasmid (phRG-TK; Promega), p53,
E2F1 expression plasmids and/or pcDNA3.1 empty
vector (control). Luciferase activity was determined
using a Dual-Luciferase Reporter assay system
(Promega) as described previously (19).
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To determine E2F1 binding to MEF promoter, nuclear
extracts from HCT116 and HEK293 cells were used for
chromatin immunoprecipitation (ChIP) assay following
the protocol described previously (20). Two micrograms
of anti-E2F1 antibody or normal rabbit IgG was
incubated with pre-cleared chromatin. Samples were
analyzed by PCR using LA Taq Polymerase (TaKaRa)
according to the recommended protocol. The primers
used (Table 4) recognize a fragment of the human MEF
promoter, CDC6 promoter or GAPDH promoter.
Immunoprecipitation and western blotting
To analyze the interaction between p53 and E2F1, trans-
fected or doxorubicin-treated HCT116 cells were lysed
with nuclear extraction buffer as previously described in
ref. 5. Nuclear extracts were incubated for 12hr at 4 C
with 2mg anti-p53 or anti-E2F1 antibodies or control IgG
immobilized in protein G Sepharose beads (Amersham
Bioscience, Sweden). Immunoprecipitates were washed,
eluted and subjected to immunoblotting, following essen-
tially our protocol reported previously (20). Blots of IP
samples or input fraction were probed with anti-p53
and anti-E2F1 antibodies or anti-g-tubulin antibody (for
input fraction). For western blotting analysis of MEF, p53
and E2F1, we used nuclear extracts of control, transfected
or treated cells. After blocking, the membranes were
probed with the appropriate antibodies, and blots were
visualized using SuperSignal (PIERCE, Rockford, IL,
USA).
Senescence induction and senescence-associated
b-galactosidase staining
To induce DNA damage-associated cellular senescence,
HCT116 p53
+/+ and p53
 /  cells were treated with
100nM doxorubicin (dox) for 24h and re-incubated in
normal medium for 3 days (for PCR analysis) or 5 days
(for staining and protein analyses) according to the
protocol reported previously (21). Cells were ﬁxed with
2% formaldehyde/0.2% glutaraldehyde and stained for
senescence-associated b-galactosidase (SA-b-gal) activity
using 5-bromo-4-chloro-3-indolyl b-D-galactoside (X-gal)
at pH 6.0 as described before (22). SA-b-gal-positive cells
were detected by bright-ﬁeld microscopy.
Animals
The p53 knockout (p53
 / ) mice were kindly provided by
Dr. Shin Aizawa from RIKEN (Kobe, Japan). The
p53-deﬁcient mice were produced through an ordinary
knockout (KO) strategy for p53 gene in C57BL/6 mice
as described earlier (23). RNA isolates from different
Table 2. Primers used for real-time quantitative RT-PCR
Gene Sense Antisense
Human MEF 50-TGGAAGGCAGTTTTTTGCTGA-30 50-GACTTCCGCGGTTGACATG-30
Human GAPDH 50-CGGGAAGCTTGTGATCAATGG-30 50-GGCAGTGATGGCATGGACTG-30
Human 18S rRNA 50-CGGCTACCACATCCAAGGAA-30 50-GCTGGAATTACCGCGGCT-30
Mouse MEF 50-TCCTGGATGAGAAGCAGATCTTCA-30 50-ATGGTGCTGCCTTTGCCATC-30
Mouse 18S rRNA 50-GTAACCCGTTGAACCCCATT-30 50-CCATCCAATCGGTAGTAGCG-30
Table 3. Primers used for the generation of mutant MEF promoter constructs
Gene Sequence
MEF prom MT1_sense 50-GACCGGGCGCCCGTGGATCCTTCCACTTCTC-30
MEF prom MT1_antisense 50-GAGAAGTGGAAGGATCCACGGGCGCCCGGTC-30
MEF prom MT2_sense 50-CTTGCCATTGGCGGCACCTAGGGTGGGAGAGC-30
MEF prom MT2_antisense 50-GCTCTCCCACCCTAGGTGCCGCCAATGGCAAG-30
Table 1. siRNA oligonucleotide sequences
Gene Sense Antisense
p53 siRNA 50-GACUCCAGUGGUAAUCUACTT-30 50-GUAGAUUACCACUGGAGUCTT-30
E2F1 siRNA 50-AAGUCACGCUAUGAGACCUCATT-30 50-UGAGGUCUCAUAGCGUGACUUTT-30
GL2 siRNA 50-CGUACGCGGAAUACUUCGATT-30 50-UCGAAGUAUUCCGCGUACGTT-30
Table 4. Primers used for ChIP assay
Gene Sense Antisense
MEF promoter 50-CTCGAGCCTCCAACTTCCCATTGG-30 50-CTCGAGGCTCAACTTCCACTTCTCC-30
CDC6 promoter 50-AAAGGCTCTGTGACTACAGCCA-30 50-GATCCTTCTCACGTCTCTCACA-30
GAPDH promoter 50-AAAAGCGGGGAGAAAGTAGG-30 50-CTAGCCTCCCGGGTTTCTCT-30
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 /  mice and age-matched
controls were used for Q-PCR analyses. The mice used
in this study were housed in a vivarium in accordance
with the guidelines of the animal facility center of
Kumamoto University. The animals were fed with chow
ad libitum. All experiments were performed according to
the protocols approved by the Animal Welfare Committee
of Kumamoto University (#A19-115).
Statistical analysis
For statistical analysis, the data were analyzed by
Student’s t-test or by one-way analysis of variance
(ANOVA) with Tukey–Kramer multiple comparison test
(JMP software, SAS Institute, NC, USA) as indicated in
each ﬁgure legend. A P-value of <0.05 is considered stat-
istically signiﬁcant.
RESULTS
p53 negatively regulates MEF expression in human cell
lines and mice tissues
MEF has been implicated in the suppression of p53 ex-
pression (16), but it is unknown whether this regulation is
reciprocal. To address this question, we ﬁrst compared the
basal level of MEF mRNA in HCT116 p53
+/+ and p53
 / 
cells. Interestingly, quantiﬁcation of mRNA showed that
the amount of MEF in HCT116 p53
+/+ cells was  5-fold
lower than in p53
 /  cells (Figure 1A). Conventional PCR
analysis also showed lower expression of MEF in HCT116
p53
+/+ cells than in p53
 /  cells (Supplementary Figure
S1A). Consistent with these observations, transfection of
p53 plasmid in HCT116 p53
 /  cells downregulated MEF
mRNA level (Figure 1B and Supplementary Figure S1B).
Treatment with nutlin-3, a speciﬁc activator of p53,
resulted in a drop in MEF mRNA expression level in
p53
+/+ cells but not in p53
 /  cells (Figure 1C).
Treatment of HepG2 cells with nutlin-3 also decreased
MEF mRNA level (Figure 1D). Conversely, knockdown
of p53 by siRNA in A549, 16HBE14o- and HEK293
cells up–regulated the mRNA expression of MEF
(Figure 1E–G). These observations implied that p53
suppresses MEF transcription. To assess whether this
decrease also occurs at the protein level, we examined
MEF expression in nuclear extracts of HCT116 p53
+/+
and p53
 /  cells. Basal MEF protein level in HCT116
p53
+/+ cells was lower than in p53
 /  cells (Figure 1H).
Exogenous addition of p53 in HCT116 p53
 /  cells
decreased the expression of MEF (Figure 1I). Moreover,
activation of endogenous p53 by nutlin-3, reduced MEF
expression in HCT116 p53
+/+ cells but had no effect on
MEF in p53
 /  cells (Figure 1J). Knockdown of p53 by
si-RNA in A549 and 16HBE14o- cells increased MEF
protein expression (Figure 1K and L). In addition, by
using tissues of p53
 /  mice, we conﬁrmed the effect of
p53 on MEF mRNA expression in vivo. Consistent with
the results in human cell lines, MEF mRNA level was
higher in various tissues of p53-deﬁcient mice than in
those of p53 wild-type mice (Figure 2A–F). These data
collectively indicated that p53 downregulates MEF
expression.
p53 suppresses MEF promoter activity
The effect of p53 on MEF expression was observed at the
mRNA level; thus, we focused on MEF promoter to as-
certain how p53 downregulates MEF. To establish the
inﬂuence of p53 on MEF promoter activity, we
co-transfected in HCT116 p53
 /  cells increasing
amounts of p53 expression plasmid and MEF promoter
(–849/+181bp). We found that increased levels of p53
caused a concomitant decline in MEF promoter activity
(Figure 3A). Next, to identify the region of MEF
promoter that is important for its response to p53, we
used three promoter constructs with varying lengths,
labeled:  800bp (–849/+181),  400bp (–384/+181) and
 200bp (–204/+181) (Figure 3B). These constructs and
p53 expression plasmid were co-transfected in p53
 / 
cells. Reporter assays revealed that activity for all three
constructs was downregulated by p53, suggesting that p53
suppresses MEF transcriptional activity by affecting at
least the  200bp proximal region of MEF promoter
(Figure 3B). However, in silico analysis of MEF
promoter did not reveal any p53 response element
within the  800bp region upstream from the transcription
start site. Intriguingly, we found E2F consensus binding
sites in this promoter region (Figure 3C). Because it was
previously demonstrated that p53 physically interacts with
and inhibits the transcriptional activity of E2F1 (24), we
hypothesized that p53 indirectly suppresses MEF tran-
scription by affecting E2F1, which could be a novel tran-
scriptional activator of MEF. To assess this possibility, we
ﬁrst investigated the effect of E2F1 on MEF expression
and promoter activity.
E2F1 is a novel MEF transcriptional activator
Introduction of E2F1 in HCT116 p53
 /  cells resulted in
dose-dependent increase of MEF mRNA level as
determined by Q-PCR (Figure 4A). Similarly, the
relative amount of MEF mRNA was upregulated by
overexpression of E2F1 in other cell lines tested
(Figure 4B–E). In contrast to E2F1 overexpression,
siRNA targeting E2F1 induced a drop in basal MEF
mRNA level in human epithelial cells (Figure 4F–H).
The upregulation of MEF mRNA by E2F1 translated to
an increase in MEF protein level as determined by western
blotting of nuclear extracts of cells transfected with E2F1
(Figure 4I and J).
To analyze the effect of E2F1 on MEF transactivation,
we co-transfected increasing amounts of E2F1 with MEF
promoter (–849/+181bp) in HCT116 p53
 /  cells. E2F1
clearly stimulated MEF transcriptional activity in a
dose-dependent manner (Figure 5A). To deﬁne the
region of MEF promoter that is controlled by E2F1, we
assessed the effect of E2F1 on three different lengths of
MEF promoter construct [as used above (–800bp,
 400bp and  200bp)]. These constructs were transfected
in HCT116 p53
 /  cells together with E2F1 expression
vector. Reporter assays revealed that the minimal region
of MEF that is activated by E2F1 is at  200bp upstream
from transcription start site (Figure 5B). The  200bp
proximal region contains two E2F binding sites
(Figure 3C). Mutation of the E2F site nearest to the
Nucleic AcidsResearch, 2011,Vol. 39,No. 1 79start site (MT1) abrogated the basal transcriptional
activity of MEF compared to wild-type promoter while
mutation of the second E2F site (MT2) did not suppress
the basal transactivation of MEF (Figure 5C). Mutation
of both sites (MT1&2) diminished the basal promoter
activity of MEF in comparison with wild-type to a level
similar to that of MT1 (Figure 5C), indicating that E2F
binding site 1 in the  200bp proximal region is important
Figure 1. p53 downregulates MEF expression in human cell lines. (A) Relative amount of MEF mRNA was examined in HCT116 p53
+/+ and
p53
 /  cells. (B) HCT116 p53
 /  cells were transfected with control pcDNA3.1 empty vector or p53 plasmid. Forty-eight hours post-transfection,
MEF mRNA level was analyzed. (C) HCT116 p53
+/+ and p53
 /  cells were untreated or treated with nutlin-3 for 24h. Total RNA was isolated for
analysis. (D) HepG2 cells were treated with 20mM nutlin-3 for 48h then total RNA was recovered. (E–G) A549, 16HBE14o- and HEK293 cells were
transfected with si-GL2 (control) or si-p53 as described in ‘Materials and Methods’ section. Total RNA was isolated and analyzed for MEF mRNA.
For (A–G) MEF mRNA level, assessed by quantitative RT-PCR, was normalized to GAPDH or 18S rRNA, which served as internal controls.
Values are mean±SD of triplicate measurements. *P<0.05; **P<0.01 versus control cells, assessed by Student’s t-test or ANOVA with Tukey–
Kramer test (for (C)). (H) Endogenous MEF and p53 protein expressions in nuclear extracts of HCT116 p53
+/+ and p53
 /  cells were examined by
western blotting. (I) HCT116 p53
+/+ and p53
 /  cells were transfected with control pcDNA3.1 empty vector, or p53 plasmid for p53
 /  cells.
Forty-eight hours post-transfection, nuclear extracts were isolated. (J) HCT116 p53
+/+ and p53
 /  cells were untreated or treated with Nutlin-3
(5mM) for 24h, then the nuclear extracts were isolated. (K and L) A549 and 16HBE cells were transfected with si-GL2 (control) or si-p53.
Forty-eight hours after transfection, nuclear extracts were isolated. For (H–L), protein levels of MEF and p53 were analyzed by western
blotting. g-tubulin was used as internal control in these experiments.
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The residual activity that was not suppressed by the
mutation of E2F site could be attributed to the effect of
Sp1, which we previously showed as a basal transcription-
al activator of MEF that binds to  91/–82 and  63/–
54bp in MEF promoter (12). To establish the association
of E2F1 on MEF promoter, we analyzed E2F1 recruit-
ment to MEF promoter by ChIP assay of nuclear lysates
from HCT116 p53
 /  cells transfected with E2F1 or
pcDNA3.1 using ChIP primers that recognize MEF
promoter region at  204/+181bp. Immunoprecipitation
with E2F1 antibody but not with control IgG and subse-
quent PCR reactions revealed the recruitment of endogen-
ous and overexpressed E2F1 to the promoter region of
MEF (Figure 5D). In addition, we veriﬁed the binding
of endogenous E2F1 to MEF promoter in HEK293 cells
(Figure 5E). Taken together, we substantiated that E2F1
is a novel MEF transcriptional activator that binds to E2F
consensus site in MEF proximal promoter region.
p53 inhibits E2F1 binding to MEF promoter
It has been demonstrated previously that the association
of p53 with E2F1 blocks the ability of E2F1 to bind to
DNA and transactivate gene expression (25). Having
shown that E2F1 binds and activates MEF promoter,
we next assessed whether p53 abrogates these effects.
Congruent with the above observations, E2F1 signiﬁcant-
ly stimulated MEF transcriptional activity when E2F1
was co-transfected with MEF promoter (–204/+181bp)
in HCT116 p53
 /  and HEK293 cells (Figure 6A and
B). However, this positive regulation was titrated away
by increasing amounts of co-transfected p53 (Figure 6A
and B). To verify the physical interaction between p53 and
E2F1, we performed immunoprecipitation (IP) using
nuclear extracts of HCT116 p53
 /  transfected with p53
and E2F1. Consistent with previous reports (24,26), we
conﬁrmed that p53 associates with E2F1 (Figure 6C).
To assess the functional consequence of this interaction,
we studied its effect on E2F1 binding on MEF promoter.
As expected, addition of p53 in HCT116 p53
 /  cells sub-
stantially lessened the steady-state association of E2F1 on
MEF promoter region as detected by ChIP analysis of
nuclear extracts (Figure 6D, left). Similar effect of p53
was also observed on CDC6 promoter (Figure 6D,
right). Because the expression level of E2F1 is relatively
similar in cells with or without p53 (Figure 6E), we ruled
out the possibility that the lack of E2F1 binding to pro-
moters in the presence of p53 was due to reduced level of
E2F1. Collectively, these data indicated that p53
downregulates MEF transcription by diminishing the
recruitment of E2F1 to MEF promoter.
Cellular senescence-induced p53 activation downregulates
MEF expression via inhibition of E2F1 binding to MEF
promoter
We next asked whether the regulation of MEF by p53 via
E2F1 occurs under physiologically relevant setting. Given
that MEF has been linked to p53 in the context of cellular
senescence (16) and considering our data above, we looked
into the possibility that senescence-activated p53 can
suppress the expression of MEF. We induced cellular sen-
escence by treating cells with DNA-damaging reagent
Figure 2. MEF mRNA level is upregulated in p53
 /  mice tissues. (A–F) Total RNA isolated from the indicated tissues of p53
+/+ and p53
 /  mice
was analyzed for the expression of MEF by real-time quantitative RT–PCR. MEF mRNA level was normalized to mouse 18S rRNA (internal
control). Results represent mean±SD (n=3). *P<0.05, **P<0.01 against p53 wild-type mice assessed by Student’s t-test.
Nucleic AcidsResearch, 2011,Vol. 39,No. 1 81Figure 3. p53 suppresses MEF promoter activity. (A) HCT116 p53
 /  cells were transiently transfected with MEF (–849/+181bp) promoter con-
struct or pGL3b vector (0.2mg) and the indicated amount of p53 plasmid or pcDNA3.1 empty vector. Luciferase activity was determined 48h after
transfection of plasmids and is expressed as fold activation over the pGL3b vector. Values are the mean±SE of triplicate platings. ***P<0.001
versus pcDNA3.1, determined by ANOVA with Tukey–Kramer test. n.s, not signiﬁcant. (B) HCT116 p53
 /  cells were transiently transfected with
the indicated MEF promoter constructs (0.2mg) and p53 plasmid (0.1mg) or pcDNA3.1 empty vector (as control). Luciferase activity was determined
48h after transfection of plasmids and is expressed as fold activation over the pcDNA3.1 vector (con) in each promoter construct. Values are
mean±SE of triplicate platings. **P<0.01; ***P<0.001 versus control, assessed by Student’s t-test. (C) The –849bp 50-ﬂanking region of MEF.
Nucleotide sequence of 50-ﬂanking region of human MEF gene is shown. The site indicated (+1) denotes the start site of the ﬁrst exon. The predicted
binding sites for E2F1 are marked on the sequence.
82 Nucleic AcidsResearch, 2011,Vol. 39,No. 1doxorubicin (dox). Treatment with moderate dose
(100nM) of dox for 24h and additional incubation for
 5 days was reported to induce cellular senescence in
HCT116 wild-type cells (21). Intense SA-b-gal staining
was observed in HCT116 p53
+/+ cells while faint
staining was seen in p53
 /  cells (Figure 7A), consistent
with the results obtained by Chang et al. (21).
Interestingly, under senescent condition, concomitant
with an enhanced level of p53, MEF protein expression
was reduced compared with control in HCT116 p53
+/+
cells (Figure 7B). On the other hand, dox treatment did
not suppress MEF in HCT116 p53
 /  cells (Figure 7B),
arguing for p53-dependency of MEF downregulation
during senescence. MEF mRNA expression in HCT116
p53
+/+ cells was also downregulated upon senescence
induction (Figure 7C). Next, we assessed the associ-
ation between E2F1 and p53 during cellular senescence
by performing IP analysis. IP using antibody speciﬁc
to E2F1 and probing with p53 antibody revealed that
cellular senescence augmented the physical interaction
between E2F1 and p53 (Figure 7D). Notably, we
detected by ChIP assay that steady-state binding of
E2F1 to MEF promoter was abolished in HCT116
p53
+/+ senescent cells (Figure 7E). Taken together, these
results suggested that under cellular senescence condition,
activated p53 downregulates MEF expression by
associating with E2F1 and inhibiting E2F1 binding to
MEF promoter.
Figure 4. E2F1 upregulates MEF expression in human cell lines. (A–E) Cells were transiently transfected with pcDNA3.1 vector (con) or the
indicated amount of E2F1 (A) or 1.0mg E2F1 (B–E). Forty-eight hours after transfection, total RNA was extracted and analyzed for MEF
mRNA expression. (F–H) si-GL2 or si-E2F1 (50nM) was transfected into the indicated cell lines and MEF mRNA expression was assessed 48h
post-transfection. For (A–H) MEF mRNA level, determined by quantitative RT–PCR, was normalized to GAPDH or 18S rRNA (internal control)
and expressed as relative amount of mRNA. Values are mean±SD of triplicate measurements. *P<0.05; **P<0.01; ***P<0.001 versus control,
assessed by ANOVA with Tukey–Kramer (A) or Student’s t-test (B–H). (I–J) MEF and E2F1 protein expressions were examined by western blotting
in nuclear extracts of HCT116 p53
 /  (I) or 16HBE14o- cells (J) transiently transfected with E2F1 or pcDNA3.1 empty vector. g-tubulin was used as
internal control.
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We have identiﬁed a dual, opposing transcriptional regu-
lation mechanism of MEF by E2F1 and p53. E2F1 acti-
vates MEF transcription by binding to E2F consensus site
in MEF promoter while p53 antagonizes this positive
interaction by associating with E2F1 and reducing its
DNA-binding activity. The extensive crosstalk between
p53 and E2F pathways is well documented (27). It was
Figure 5. E2F1 increases MEF promoter activity by binding to E2F site. (A) HCT116 p53
 /  cells were transiently transfected with MEF (–849/
+181bp) promoter construct or pGL3b vector (0.2mg) and the indicated amounts of E2F1 plasmid or pcDNA3.1 empty vector. Luciferase activity
was determined 48h after transfection and is expressed as fold activation over the pGL3b vector. Values are the mean±SE of triplicate platings.
yyyP<0.001 versus pGL3b; ***P<0.001 versus pcDNA3.1, determined by ANOVA with Tukey–Kramer. (B) HCT116 p53
 /  cells were transiently
transfected with the indicated MEF promoter constructs (0.2mg) and E2F1 plasmid or pcDNA3.1 vector (0.1mg). Luciferase activity was determined
48h after transfection and is expressed as fold activation over the pcDNA3.1 vector in each promoter construct. Values are mean±SE of triplicate
platings. ***P<0.001 versus control, assessed by Student’s t-test. (C) HCT116 p53
 /  cells were transfected with 0.2mg pGL3b vector or MEF (–
200/+181bp) promoter wild-type (WT), MT1, MT2 or MT1&2. (Left) MT1, MT2 represent MEF (–200/+181bp) promoter containing mutated E2F
site. Luciferase activity was determined 48h after transfection and is expressed as fold activation over pGL3b vector. Values are mean±SE of
triplicate platings. ***P<0.001 versus WT, assessed by ANOVA with Tukey–Kramer test. (D) E2F1 binding on MEF promoter was determined by
ChIP assay using nuclear extracts of HCT116 p53
 /  cells transiently transfected with E2F1 or pcDNA3.1 vector (1.0mg). CDC6 promoter was used
as positive control and GAPDH promoter was used as negative control for E2F1 binding. Upper panel illustrates the MEF promoter region (–
204bp/+181bp) in which binding was assessed. (E) Nuclear extract from HEK293 cells was used to assess the endogenous binding of E2F1 on MEF
promoter. CDC6 and GAPDH promoters were used as positive and negative controls, respectively.
84 Nucleic AcidsResearch, 2011,Vol. 39,No. 1described earlier by O’Connor et al. (24) that E2F1 and
p53 reciprocally inhibit each other’s transcriptional
activity through their physical association, probably
forming a protein–protein complex and thereby prevent-
ing DNA binding. E2F1 and p53 are also known to
control genes that inﬂuence cell cycle progression
(24,27). Indeed, we found here that their interaction
(Figures 6C and 7D) affects the regulation of MEF, a
molecule that is involved in the transition of cells from
G1 to S phase (7) and in driving quiescent hematopoietic
stem cells to G1 phase (14). We also noted that exogenous
addition of p53 slightly lessened the recruitment of E2F1
to the promoter of CDC6 (Figure 6D), an E2F1 target
gene that regulates the early steps of DNA replication
(28–30), raising the possibility that p53 interferes with
the transcription of genes other than MEF that are
targeted by E2F1. Being two pivotal regulators of cell
proliferation, the functional interaction between E2F1
and p53 most likely affects cell fate.
Sashida et al. (16) has demonstrated that MEF de-
creases p53 protein stability by inducing the transcription
of MDM2, and MEF also downregulates Rb, an endogen-
ous inhibitor of E2F1. Because the loss of MEF substan-
tially enhanced the senescent phenotype of murine
embryonic ﬁbroblasts and activated the p53 function, it
was evident that MEF inhibits cellular senescence by
Figure 6. p53 inhibits E2F1 binding to MEF promoter and reduces E2F1-induced MEF promoter activation. (A and B) HCT116 p53
 /  and
HEK293 cells were transiently transfected with MEF (–204/+181bp) promoter construct or pGL3b vector (0.2mg), pcDNA3.1 or E2F1 (0.1mg) and
the indicated amounts of p53 plasmid. Luciferase activity was determined 48h after transfection and is expressed as fold activation over the pGL3b
vector. Values are the mean±SE of triplicate platings.
yyyP<0.001 versus pGL3b;
###P<0.001 versus pcDNA3.1; *P<0.05; ***P<0.001 versus
E2F1, determined by ANOVA with Tukey–Kramer. (C) HCT116 p53
 /  cells were transiently transfected with p53 and E2F1 plasmids. Nuclear
extracts were analyzed for p53-E2F1 association by IP using antibody speciﬁc to p53, E2F1 or control mouse IgG. Immunoprecipitates were loaded
onto SDS–PAGE gel, blotted and probed with E2F1 or p53 antibodies. (D) HCT116 p53
 /  cells were transiently transfected with E2F1 and p53
plasmid or pcDNA3.1 empty vector. Nuclear extracts were isolated and used for ChIP assay to determine E2F1 binding on MEF promoter
and CDC6 promoter in the presence or absence of p53. (E) Endogenous protein level of E2F1 was examined in nuclear extracts of HCT116
p53
+/+ and p53
 /  cells. g-Tubulin was used as internal control.
Nucleic AcidsResearch, 2011,Vol. 39,No. 1 85suppressing p53 pathway (16) (Figure 7F, right diagram).
However, whether this occurs at steady state or induced
by pathogenic/pathological condition is still unclear (16).
The previous study showing that MEF downregulates p53
combined with our data here showing that MEF mRNA
and protein levels were suppressed by p53 implies that a
negative regulatory mechanism exists between MEF and
p53 pathways. We propose that during DNA damage,
Figure 7. p53 suppresses MEF expression during cellular senescence. (A and B) HCT116 p53
+/+ and p53
 /  cells were treated with doxorubicin
(Dox) for 24h and incubated for 5 days to induce cellular senescence. Cells were ﬁxed and stained with X-gal to detect SA-b-gal activity. Stained cells
were photographed at phase contrast with 20-fold magniﬁcation (Scale bar, 100mm) (A). The nuclear extracts from Dox-treated or untreated cells
were subjected to immunoblotting using the indicated antibodies. g-tubulin was used as internal control (B). (C) HCT116 p53
+/+ cells were untreated
or treated with Dox for 24h and incubated for 3 days. Total RNA was recovered and MEF mRNA expression was examined by Q-PCR. Amount of
MEF mRNA was normalized to GAPDH and expressed as relative amount compared to control cells. Values are mean±SD of triplicate platings.
**P<0.01, determined by Student’s t-test. (D) Cellular senescence was induced in HCT116 p53
+/+ cells by doxorubicin treatment similar to (A). p53
binding to E2F1 was examined by immunoprecipitation of nuclear extracts. (E) E2F1 binding on MEF promoter was examined by ChIP assay using
nuclear extracts of control or Dox-induced senescent HCT116 p53
+/+ cells. (F) Negative regulatory mechanism between p53 and MEF. (Left) DNA
damage stimulates p53 that enhances its binding to E2F1. This leads to reduced recruitment of E2F1 to the MEF promoter and the suppression of
MEF transcription. (Right) MEF upregulates MDM2 (described in ref. 16), which inhibits p53.
86 Nucleic AcidsResearch, 2011,Vol. 39,No. 1p53 is activated and interacts with E2F1, which minimizes
E2F1 recruitment to MEF promoter (Figure 7F, left
diagram). The lessening of MEF levels may partly contrib-
ute to the modulation of cell cycle progression. We
showed here that p53 affects MEF transcription indirectly,
but the possibility that p53 can also directly affect MEF at
the post-translational level cannot be fully ruled out.
Until now, the regulation of MEF protein stability
mediated by cyclin A is the only known molecular event
by which MEF is controlled especially during cell cycle
(7). Our data here indicated that MEF transcription is
also inﬂuenced by E2F1, an activator E2F family
member that affects the cell cycle (31,32). Thus, mechan-
isms of controlling MEF exist at both transcriptional and
post-translational levels. Because E2F1 binds to MEF
promoter and mutation of E2F binding site inhibited
basal MEF promoter activity, MEF may be considered
a target of E2F1 transcription factor. While it is possible
that E2F2 and E2F3, which are also trans-activating
E2Fs, can affect MEF, we found that speciﬁc silencing
of E2F1 efﬁciently suppressed endogenous MEF mRNA
level, suggesting a considerable speciﬁcity of E2F1 where
transactivation is concerned. However, although we
observed that MEF transcription was reduced by p53 at
the organismal level (Figure 2), the effect of E2F1 on
MEF in vivo still awaits veriﬁcation. As far as we know,
MEF is the ﬁrst member of the Ets transcription factor
family to be identiﬁed as a direct E2F target gene despite
the fact that Ets transcription factors are notable for their
roles in cellular growth and proliferation (1). It might not
be surprising that future research efforts will unveil direct
molecular links between members of E2F and Ets families.
Interestingly, it was reported that p53 downregulates Ets1
and Ets2 at transcriptional level, although the molecular
mechanism for this downregulation has not been
elucidated (33). As our transcription factor search
yielded a few E2F consensus sites in their promoter
regions (data not shown), E2F might participate in the
regulation of Ets1 and Ets2—this possibility remains to
be explored.
MEF has been proposed to be a tumor suppressor
(13,34) and an oncogene (35). This conundrum has
remained unresolved. The differences in the observed
functions of MEF may be due to different tumor tissues
used and the context on which the activities of MEF were
identiﬁed. In tumor tissues wherein constitutive activation
of E2Fs occurs due to dysregulation in the Rb pathway
(36), MEF may contribute to amplify the proliferative
function of E2F1 likely by inhibiting p53. However, this
supposition may not necessarily mean that MEF is an
oncogene (in terms of E2F1 regulation) because
E2F1
 /  mice have increased susceptibility to tumorigen-
esis in different tissues (37,38). Being caught in between
the complex crosstalk of E2F/Rb and p53 pathways,
deﬁning the role of MEF either as tumor suppressor or
as oncogene requires further extensive study.
In conclusion, we identiﬁed E2F1 as a novel MEF tran-
scriptional activator and p53 as a modulator of this acti-
vation. Especially in the context of cellular senescence,
as MEF was previously shown to inhibit p53, we have
now shown that p53 reciprocally opposes MEF
transactivation.
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